Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Envoy Medical (COCH) EBITDA Margin (2022 - 2026)

Envoy Medical's EBITDA Margin history spans 5 years, with the latest figure at 11158.97% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 30680.0% to 11158.97% in Q1 2026 year-over-year; TTM through Mar 2026 was 9877.35%, a 66933.0% decrease, with the full-year FY2025 number at 9856.02%, down 61157.0% from a year prior.
  • EBITDA Margin hit 11158.97% in Q1 2026 for Envoy Medical, down from 8781.33% in the prior quarter.
  • Over the last five years, EBITDA Margin for COCH hit a ceiling of 1952.5% in Q3 2023 and a floor of 57405.0% in Q4 2022.
  • Historically, EBITDA Margin has averaged 12838.97% across 5 years, with a median of 10644.64% in 2024.
  • Biggest five-year swings in EBITDA Margin: soared 5225026bps in 2023 and later crashed -1259714bps in 2024.
  • Tracing COCH's EBITDA Margin over 5 years: stood at 57405.0% in 2022, then skyrocketed by 91bps to 5154.74% in 2023, then tumbled by -113bps to 11000.0% in 2024, then grew by 20bps to 8781.33% in 2025, then dropped by -27bps to 11158.97% in 2026.
  • Business Quant data shows EBITDA Margin for COCH at 11158.97% in Q1 2026, 8781.33% in Q4 2025, and 15435.71% in Q3 2025.